Medical Stock Investing News
On March 1, 2012 the Bill Chippas Investing News Radio Show featured IntelliCell BioSciences, Inc. (Symbol SVFC), a pioneering regenerative medicine company focused on the expanding regenerative medical markets.
IntelliCell BioSciences develops a portfolio of products and services that targets a wide and diverse regenerative, preventative, and curative medical market including age related disease states to sports related injuries.
IntelliCell’s process is a patent-pending non-enzymatic method for deriving stromal vascular fraction from adipose tissue (your own fat). IntelliCell’s process dramatically increases the yield by 10 to 20 times in manufacturing compared to methods in use today. These mixtures of cells have multiple functions and are highly integrated and it’s likely, more potent than the adipose stem cells by themselves.
IntelliCell BioSciences Inc. offers Intellicell™, a treatment for the correction of lines, wrinkles, and dermal defects, as well as for various treatments, including anti-aging, scarring, burns, and non-healing wounds; stem cell product candidates for treating aging dermal skin; and product candidates in the areas of osteoarthritis, cartilage and meniscus regeneration, and general dermal regeneration, the applications for its product are wide and diverse,
IntelliCell BioSciences, Inc. is based in New York, New York.IntelliCell intends to initially focus on selling laboratory suites and licensing its technology to doctors for use in their offices for their patients. The company is also setting up Centers of Excellence where doctors can treat their patients.
IntelliCell announced last month it licensed its proprietary, patent pending technology to RegenaStem Inc., a Canadian Federally Incorporated Company, with offices in Ontario, The license calls for investing a minimum of $500,000 to a maximum of $1.5 million into IntelliCell BioSciences and paying royalties of 30% of net revenue.The company is also starting FDA IND clinical trials at major medical centers for clinical indication approval, some potential centers are; Emory, Georgia Tech, Mt Sinai Medical Center , NYU and Tulane. IntelliCell intends to pursue expansion to secondary markets and beyond the U.S. through a combination of company-owned and licensed clinical facilities.
Watch Show recording: http://www.ustream.tv/recorded/20812678
Listen to Show Recording: http://billchippasshow.com/2012/bcshow03012012.mp3
For additional information
or call Princeton Research at
Rule 17B Requirements — Disclosure of Payment for Investor Relations– Princeton Research has contracted to receive 10,000 restricted shares from IntelliCell BioSciences for investor relations.